Articles tagged with Vaccine Development
The World Health Organization has prequalified the India-made rotavirus vaccine ROTAVAC, which will be available for procurement by UN agencies and Gavi for use in low-resource countries. The vaccine is the result of a unique social innovation partnership between Indian and international researchers, public, and private sectors.
Research connects preterm birth to adult heart disease by showing that fetal infection and inflammation disrupt genes crucial for normal heart development. This study uses a preterm animal model to demonstrate how inflammation can lead to incomplete heart development, increasing the risk of abnormal heart rhythms and heart failure.
The World Health Organization has prequalified the Typbar-TCV typhoid conjugate vaccine, offering longer-lasting protection and allowing administration to children under two years old. This step is crucial in expanding access to this lifesaving vaccine and reducing the burden of typhoid in high-risk areas.
The Michelson Prizes aim to support young scientists developing groundbreaking approaches to defeat major global diseases. Two $150,000 prizes will be awarded in June 2018 to identify innovative projects beyond conventional approaches.
A high-dose live oral vaccine has been found to be more effective in rapidly protecting individuals from cholera than the standard two-dose killed vaccine approach. This breakthrough could lead to improved control of outbreaks and lower mortality rates, particularly in low-income countries.
A new Army-developed Zika vaccine has induced a robust immune response in healthy adults, with over 90% of volunteers developing an immune response against the virus. The vaccine, developed by Walter Reed Army Institute of Research, was tested in three phase 1 studies and showed promising results.
Researchers have developed an inactivated Zika purified virus (ZPIV) vaccine that induced an immune response in participants and was well-tolerated, according to Phase 1 clinical trial results.
A gene-based Zika vaccine developed by NIH scientists has been found to be safe and immunogenic in healthy adults, with 60-89% of participants generating a neutralizing antibody response. The vaccine, which includes a small piece of DNA called a plasmid, triggers the body to mount an immune response when injected into muscle.
The Human Vaccines Project has reported high-level outcomes from two concurrent clinical studies aimed at deciphering the components and mechanisms of human immunity. The findings may provide important new insights into human immunity, which will be leveraged to launch expanded studies in 2018.
Scientists at IAVI and TSRI published new findings on HIV-blocking antibodies, shedding light on their development and potential as a vaccine design. The research highlights the importance of understanding how neutralizing antibodies develop to create an optimal vaccine strategy.
Scientists developed an enterovirus vaccine that protects against virus-induced diabetes in a mouse model for Type 1 diabetes. The study suggests the potential role of enteroviruses in human Type 1 diabetes and offers a new preventative treatment option.
Researchers are developing a universal influenza vaccine that would protect against all strains of flu globally. Current vaccines have varying effectiveness, with some years seeing only 10% effectiveness.
Researchers have developed a novel reagent to detect rare B cells indicating successful vaccination in veterinary animals. The method will be widely applicable for demonstrating immunity to other veterinary pathogens.
A promising leprosy vaccine candidate, LepVax, is moving into human trials after years of research. The vaccine has been developed using cutting-edge technologies to induce protective responses against the disease.
Researchers have discovered that the virus used in the early smallpox vaccine was closely related to horsepox, contradicting centuries-long assumptions that cowpox was used. The finding has significant implications for our understanding of vaccine development and its applications in modern medicine.
A combination of pathogen-specific, platform-based, and prototype-pathogen approaches is crucial for effective pandemic preparedness. These methods enable rapid deployment of diagnostics, treatments, and vaccines to stop outbreaks in their tracks.
A new phase 2b trial of the Vi-conjugate typhoid vaccine shows high efficacy rates and reduced symptoms of typhoid disease. The vaccine has been shown to be safe and immunogenic, with a potential to halve typhoid infections in children under 2 years old.
Recent advances in engineering bacterial outer membrane vesicles have demonstrated protection against infection by various bacterial species in animal models. These biologically-derived nanoparticles could function as a platform technology for vaccine development and targeted compound delivery.
Researchers create novel microparticles that can deliver multiple doses of a drug or vaccine with just one injection, using a biocompatible polymer and custom-built 3D printing method. The particles release drugs or vaccines at specific time intervals, mimicking the way a series of vaccines would be given, potentially improving patient...
Researchers identified a signature of five early innate immune markers correlating with antibody titers after vaccination, providing insight into VSV-based vaccine efficacy. The study's findings could lead to accelerated vaccine development and improved emergency vaccine strategies.
The University of Arizona Health Sciences has received a $4.8 million grant from the National Institute of Allergy and Infectious Diseases to develop a live vaccine for Valley fever. Scientists aim to test the vaccine in dogs, with potential next steps including human evaluation and approval.
Researchers explore the origins of the smallpox vaccine, tracing its development from cowpox virus to modern vaccinia virus. The study sheds light on the intricate relationships between different types of viruses and lymphs involved in the vaccine's evolution.
Researchers at Arizona State University have developed a plant-based Zika vaccine that is more potent, safer and cheaper to produce than existing alternatives. The vaccine targets the DIII domain of the Zika virus and has been shown to induce 100% protection against multiple Zika virus strains in mice.
Researchers at the University of Maryland School of Medicine are developing a vaccine to protect against Shigella and certain E. coli, leading causes of diarrheal diseases in young children and travelers. The $2.47 million grant will support translation from an animal-tested prototype to a human-ready vaccine for Phase 1 clinical trials.
Dr. Sang-Moo Kang's project aims to improve the efficacy and extent of cross protection against new influenza virus strains by incorporating M2e epitopes into HA molecules. The research will test novel approaches to boost cross protective properties of licensed seasonal influenza vaccines, with results expected to impact public health.
Researchers found that breaking a barrier to autoimmune disease also enables the production of antibodies capable of neutralizing HIV-1. The study, published in The Journal of Experimental Medicine, suggests a potential new approach for developing an HIV vaccine.
A study published in The Lancet found that exposure to the meningococcal group B vaccine reduced the likelihood of contracting gonorrhoea by approximately 31%. This is the first time a vaccine has shown any protection against gonorrhoea, offering a new avenue for vaccine development.
A recent study by Duke University researchers demonstrates a vaccine approach that appears to protect fetuses from congenital CMV infection. The findings, published in JCI Insight, suggest potent antibodies can prevent viral transmission and severe disease in developing fetuses.
A recent study published in Frontiers in Cellular and Infection Microbiology has made significant progress in developing a DNA vaccine against the dengue virus. Researchers have successfully induced persistent humoral and cellular immune responses in mice, providing efficient protection against lethal challenge from one of the four ser...
Researchers develop a microneedle patch for flu vaccination, producing robust immune responses and eliminating injection discomfort. The patch is safe, easy to administer, and can be delivered in the mail, with potential economic and manufacturing advantages.
Researchers analyzed over 1.3 million HZ-related ED visits from 2006 to 2013, finding a significant increase in utilization and costs, especially among younger adults. Vaccination was linked to reduced ED utilization, but further research is needed to understand the drivers of increased costs.
A new Zika virus vaccine has shown 100% protection in mice, utilizing the NS1 protein. The vaccine's effectiveness was demonstrated through a single-dose immunization strategy.
A 10-year Lassa virus research project has yielded structural and functional details of a key viral surface protein, which could help advance development of Lassa vaccines. The study provides the first detailed view of the Lassa glycoprotein precursor complex bound to a human neutralizing antibody.
Researchers at EMBL and ESPCI Paris have developed a new technique to rapidly sort HIV viruses, which could significantly speed up vaccine development. The system enables the analysis and sorting of hundreds of HIV viruses per second, allowing for rapid testing of millions of viral variants.
A Canadian researcher has received a $3.99 million grant to develop an HIV vaccine candidate in partnership with IAVI. The team aims to improve upon a promising candidate and advance it to clinical testing in human volunteers.
Scientists have created a vaccine that boosts specific parts of the immune system attacking HIV viral genes, prolonging resistance and allowing for more efficient defense. This approach may lead to an effective HIV vaccine by targeting weak immunostimulatory parts of viruses.
Researchers have identified three mutations that enable TB pathogens to develop rapidly in immunocompromised individuals. These emerging strains require new treatment approaches, including genetically engineered vaccines that consider a patient's immune status and pathogen virulence features.
Researchers at City College of New York and TechnoVax have successfully developed a vaccine against the Zika virus using a novel virus-like particle (VLP) technology. The VLP formulations were found to be highly effective in eliciting protective antibodies while being well-tolerated and safe.
The European Centre for Disease Prevention and Control (ECDC) has released a survey report on immunisation information systems, showing strong potential for e-health to increase vaccination coverage. Digital systems are being piloted across EU/EEA countries, including automated reminders that can identify under-vaccinated populations.
A research team has identified a key molecular target that regulates antibody production in both helper and regulatory T cells, which may lead to the development of new treatments for autoimmune diseases like lupus and rheumatoid arthritis.
A new report emphasizes the importance of prioritizing rapid diagnostic tests for life-saving diseases, similar to pregnancy tests. The tests can help tackle antibiotic resistance and improve global health. However, lack of funding and profile are major barriers to their widespread adoption in low- and middle-income countries.
A new vaccine called Zoonoses Barrier Vaccine (ZBV) aims to prevent the spread of highly pathogenic zoonotic diseases. The vaccine targets deadly pathogens in animal species and has shown promise in preventing devastating diseases such as Lassa haemorrhagic fever, SARS, MERS, plaque, Rift Valley Fever Virus and Q Fever.
A new live-attenuated Zika vaccine has been successfully developed in mice, offering complete protection against the virus after a single dose. The vaccine's safety profile is promising, with no adverse effects observed in mice compared to other clinically approved vaccines.
Researchers developed a new method for programming proteins used in vaccines against infectious diseases, enabling stable production and lower costs. The approach has shown promising results in animal trials, provoking a protective immune response.
Persistent stockouts and exposure to freezing temperatures are among problems in outdated vaccine supply chains, according to researchers. The challenges hinder the impact of vaccines on safeguarding people's health, with one in three countries experiencing at least one stockout of a vaccine for at least one month.
Scientists at TSRI have developed a method to analyze the glycan shield on HIV's protective outer glycoprotein, enabling the creation of a 'fingerprint' to identify potential vaccine targets. The new method saves time and has revealed that the glycoprotein does not have as many holes as previously predicted.
A Phase 1 clinical trial found that a two-vaccine regimen against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers. The investigational vaccines used harmless viral vectors to deliver proteins of the Ebola virus, prompting an immune response.
Researchers at GW University have developed a new relative potency testing program for the Na-GST-1/Alhydrogel hookworm vaccine, showing it remains stable and immunogenic after five years of storage. This innovation aims to improve vaccine effectiveness in developing countries where hookworm infections are prevalent.
A study published in the Public Library of Science Pathogens found that Zika virus targets neuronal, lymph, joint, muscle and genital/urinary/reproductive tissues, persisting for at least 35 days. The research provides insights into the growth and distribution of the virus in human tissues.
A study published in AIMS Public Health estimates that the 1962 human cell strain breakthrough saved nearly 10 million lives and prevented over 4.5 billion cases of disease globally through vaccination. The development enabled vaccines to be produced safely, leading to widespread vaccination against multiple infections.
Researchers developed a new relative potency testing program to study the potency of vaccines for tropical diseases. The program found that the Na-GST-1/Alhydrogel Hookworm Vaccine was potent over 60 months of storage, with increased potency in humans living in endemic areas.
A new article recommends establishing an institute focused on developing vaccines of public health importance without commercial interest. The proposed institute will require collaboration among stakeholders from industry, government, academia, and private foundations.
The MIT-led project aims to standardize vaccine manufacturing at globally affordable costs by combining automation and reducing labor costs. The goal is to produce vaccines for less than 15 cents a dose, with the potential to make global vaccination more accessible.
Researchers have discovered a new class of compounds that kill adult and egg stages of the human whipworm, a parasite infecting 500 million people. These compounds could lead to effective treatments and vaccines for whipworm infections, which cause physical and mental damage.
In less than a year, researchers have developed multiple vaccine platforms providing robust protection against Zika virus challenge in animal models. However, safety considerations and unique challenges associated with the virus must be addressed in clinical development.
Researchers compared informed consent quality in clinical trials of a hookworm vaccine conducted in Brazil and the US. Despite differences in education and healthcare access, there were few statistically significant differences in consent quality between participants in urban and rural locations.
A Queensland-led team has developed an effective and economical Ebola treatment made with antibodies from horses, which could be used in the next outbreak. The post-exposure treatment is a cost-effective alternative to monoclonal antibodies, which require significant investment for scale-up and manufacture.
Researchers at Johns Hopkins Bloomberg School of Public Health identified a mechanism by which the chikungunya virus controls infection severity. The study found that all alphaviruses and coronaviruses may work in the same way, and that breaking a specific protein bond can prevent viral replication.
Researchers have developed a new method to produce stable poliovirus protein shells, which can be used as vaccines and do not require growing live viruses. The shells have been shown to induce high levels of protective antibodies in mice and rats.
A global partnership, CEPI, aims to create vaccines for emerging infectious diseases with a $460m initial investment from governments and foundations. The Coalition will target MERS-CoV, Lassa, and Nipah viruses, as well as Ebola and Zika, to develop safe and effective vaccines that can be deployed rapidly to contain outbreaks.